logo
Illegal liquor outlets thrive in protected forests in Faridabad

Illegal liquor outlets thrive in protected forests in Faridabad

Time of India3 days ago
: Liquor vends and taverns are operating openly on Aravali forest land and protected greenbelts across Faridabad, some hidden behind thick vegetation, others right in the middle of residential zones, in clear violation of environmental laws.
Tired of too many ads? go ad free now
At least four vends have come up on forest land, and over 35 more in green belts in areas like Bhatola, Mangar, Surajkund Road and Lakkarpur.
Many of these locations fall within buffer zones of the Aravalis, where any construction or commercial activity is either restricted or banned under the Punjab Land Preservation Act (PLPA), 1900.
The vends are not small kiosks. In most places, there are permanent structures -- double-shutter shops with paved courtyards, tin-roofed seating areas and boundary walls.
Ahatas attached to them offer open-air drinking spaces with plastic chairs, wooden benches and food counters. In some cases, drains around the premises were clogged with empty bottles, plastic cups, leftover food items and liquor sachets.
One of the outlets in Bhatola lies on protected forest land, which is owned by the irrigation department. Another store in a forest area is located close to the Manav Rachna University, and a third in Lakkarpur is on Aravali land owned by the tourism department.
A fourth outlet is carved out of a green belt in Mangar, with a parcel of Aravali land likely flattened to make space for the shop. The store's owners also installed floodlights here.
On Friday, most staffers at these stores refused to talk or show any permits.
But an employee of a wine shop along Surajkund Road told TOI the store has been at the spot for years. "No one came to say that it is illegal," he said. Another staffer at the wine shop in Mangar said he wasn't aware that this was forest land.
Tired of too many ads? go ad free now
An excise department official on Friday refused to comment on the legality of these shops. "The matter is sub-judice. A verification survey can be initiated soon," a district excise official said.
A forest department official said on Friday that they had issued notices to these vends last week.
"These are old structures, but we issued notices last week. One of them, which is near Surajkund Road, has around 20% of its structure in PLPA area.
We will carry out a demarcation and issue a notice. The Mangar one is in section 4 of PLPA. We will carry out appropriate action against these units," said Vipin Kumar Singh, divisional forest officer, Faridabad.
The matter of liquor vends operating illegally in protected forests had reached the National Green Tribunal (NGT) in Dec last year. Faridabad-based activist Narender Sirohi had filed a petition, alleging that the state govt has allowed rampant commercialisation of protected Aravali land.
"These outlets are polluting forest land and green belts, creating constant nuisance and encouraging illegal commercial activities in areas where only afforestation or open land use is permitted. Despite multiple complaints, no action was taken. That's why I approached the tribunal," Sirohi told TOI.
He said that these shops were not "accidental violations", these laid bare "regulatory apathy".
"Entire green belts are loaded with heaps of garbage… Such activities are not only causing degradation of the environment, but are also affecting public health at large," he added.
For now, NGT has sought responses from the forest department, Haryana State Pollution Control Board (HSPCB), excise department, district administration and the Union environment ministry. A hearing is expected by Oct.
Environmentalists said such commercial operations in forest areas were "environmental vandalism".
"Govt talks of preserving green belts, but liquor outlets are being allowed to thrive in the very areas meant for reforestation and ecological buffers," said Sunil Harsana, an ecologist and activist.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud
FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud

Hindustan Times

time27 minutes ago

  • Hindustan Times

FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud

MUMBAI: A 65-year-old businessman from Powai lost ₹52 lakh after an allegedly Japanese woman he befriended online convinced him to invest in Bitcoins and duped him in a cybercrime fraud for a month. The West Cyber police had initially received his complaint, and as the defrauded amount was less than ₹1 crore, they forwarded it to the Andheri police station, which registered a case against the woman and her accomplices on Saturday. From the last week of June to July 17, the victim invested ₹ 52 lakh.(HT File Photo) According to the complaint, the businessman received a Facebook friend request from an unknown person in June. The profile had a woman's photo and displayed her employment with IBM in Hong Kong. Believing it to be genuine, the complainant accepted her request, and the two began communicating through the messenger app. Also Read | Senior citizen loses ₹21 lakh to gaming fraud During their conversation, the accused asked for his mobile number, and the two began to speak with each other on the phone. Her soft-spoken manner on calls gained the complainant's trust, he said in the complaint. She told him she was currently working in an IBM office based in Hong Kong and that she would soon be joining the IBM Crypto trading platform in Japan as a manager. The complainant continued to talk with her for 10 more days about various subjects. She would tell him how investing in Bitcoin reaps huge profits and how it could benefit him. Though the complainant was initially reluctant, he was eventually convinced. Also Read | Businessman duped of ₹8.75 crore in a forex trading fraud Once the complainant expressed interest, she sent him a link and asked him to create an ID for his virtual account. He said he began investing money in Bitcoins through the bank accounts she provided. From the last week of June to July 17, he had invested ₹52 lakh. When he checked the application, it displayed ₹10.3 crore as his virtual bank account balance. Noticing huge returns, the 65-year-old wanted to, but could not invest more money in Bitcoins. So, he decided to withdraw the balance accumulated in his account. When he inquired about the withdrawal process, he was asked to pay a 30% tax first. Finding this suspicious, he discussed it with his relatives and realised he had been defrauded. Also Read | Fraud impersonates bizman's US-based brother, swindles ₹50k The complainant first contacted the Cyber Helpline number 1930 and filed a complaint. The Andheri police on Saturday registered a case under sections 66 (d) (dishonestly receiving stolen computer resource or communication device) of the Information Technology Act, 2000, and sections 318 (4) (cheating), 319 (2) (cheating by personation), 336 (2) and 336 (3) (forgery), 338 (forgery of valuable security documents), 340 (2) (using forged electronic document as genuine) and 61 (2) (criminal conspiracy) of the Bhartiya Nyaya Sanhita, 2023. 'We are trying to ascertain the identities of and trace the accused through the transactions made by the complainant,' said a police officer from Andheri police station.

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Economic Times

time30 minutes ago

  • Economic Times

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY

China's Ant to exit Paytm in ₹3.8k cr deal
China's Ant to exit Paytm in ₹3.8k cr deal

Time of India

time43 minutes ago

  • Time of India

China's Ant to exit Paytm in ₹3.8k cr deal

Mumbai: China's Ant Group will exit Paytm by selling its remaining 5.8% stake in the company through one or more block deals worth at least Rs 3,800 crore (about $434 million) on Tuesday, a term sheet showed. Tired of too many ads? go ad free now Ant Group (formerly Ant Financial), one of the early investors of the Noida-based fintech is an affiliate of Chinese tech giant Alibaba Group. After this deal, Paytm will have no Chinese ownership. Ant Group will sell about 3.7 crore shares in Paytm at a floor price of Rs 1,020 per share, a 5.4% discount to Paytm's closing price of Rs 1,078 on the NSE on Monday. Paytm declined to comment. Ant Group has been paring its exposure to the fintech - it sold a 4% in the company through block deals worth over Rs 2,000 crore in May this year. In 2023, Paytm founder Vijay Shekhar Sharma had bought a 10.3% stake in the firm worth $628 million from Ant Group to shore up his stake in the company and cut Chinese ownership. Alibaba had exited Paytm through a block deal in early 2023. "There's been a trend among Indian companies to reduce Chinese shareholding given the broader national sentiment," said an analyst on condition of anonymity. Sharma holds about a 9% stake in the firm, recent shareholding data showed. Paytm, which had come under regulatory scrutiny last year following RBI's move to wind down its banking unit due to non-compliance, swung back to profit in the June quarter. Over the past couple of years, SoftBank and Berkshire Hathaway exited Paytm. "From an investment standpoint, Ant Group perhaps doesn't see the same potential in Paytm compared to its first investment," independent fintech consultant Parijat Garg told TOI.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store